BofA lowered its price target for Krystal Biotech, citing growth concerns in August 2025.
1 report, 1 independent
Updated Aug 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BofA lowered its price target for Krystal Biotech, citing growth concerns in August 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Krystal Biotech, Inc.
biotechnology company
Nothing else this week.
-
Bank of America
American multinational banking and financial services corporation
Related events
- Bank of America raised its price target following positive news regarding Alvotech, a licensing agreement for biosimilar commercialization, and the FDA closing an inspection after quality issues.
- Bank of America analysts covered Micron Technology, raising price targets after the company beat EPS estimates and forecasting HBM market growth.
- Bank of America reiterated its Buy rating and maintained the price target for Costco on May 27, 2026.
- Stephens and Bank of America raised price targets for Darden Restaurants.
- Bank of America and Raymond James Financial raised their ratings and increased price targets for Okta.
Coverage
Newest first; wire copies grouped- TipRanksKrystal Biotech price target lowered to $182 from $192 at BofA BofA analyst Alec Stranahan lowered the firm’s price target on Krystal Biotech (KRYS) to $182 from $192 and keeps a Buy rating on the sh